Katarzyna Kozdon1, Caroline Fitchett1, Geoffrey E Rose2, Daniel G Ezra3, Maryse Bailly1. 1. Department of Cell Biology UCL Institute of Ophthalmology, London, United Kingdom. 2. Orbital clinic, Moorfields Eye Hospital and the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom. 3. Department of Cell Biology UCL Institute of Ophthalmology, London, United Kingdom 2Orbital clinic, Moorfields Eye Hospital and the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and.
Abstract
PURPOSE: Graves' orbitopathy (GO) is a sight-threatening autoimmune disorder causing extraocular muscle fibrosis, upper lid retraction and eye bulging due to orbital fat expansion. These clinical features are mediated by aspects of orbital fibroblasts differentiation, including adipogenesis and fibrosis. Our previous work suggested that this dual phenotype might be a manifestation of mixed cell populations, partially linked to the expression of mesenchymal stem cell (MSC) marker CD90. Thus, we set out to determine whether GO orbital fibroblasts displayed MSC properties. METHODS: Control and GO orbital fibroblasts previously characterized for CD90 and CD45 expression were analyzed by flow cytometry for classical MSC positive (CD73, CD105) and negative (CD14, CD19, HLA-DR, and CD34) markers. Graves' orbitopathy fibroblasts were tested further for their ability to undergo lineage specific differentiation following standard protocols. RESULTS: Control and GO fibroblasts strongly expressed CD73 and CD105, with a higher percentage of positive cells and stronger expression levels in GO. Neither cell type expresses CD14, CD19, and HLA-DR. Protein CD34 was expressed at low levels by 45% to 70% of the cells, with its expression significantly lower in GO cells. Graves' orbitopathy fibroblasts displayed features of osteogenesis (calcium deposits, and osteocalcin [BGLAP] and osteonectin [SPARC] expression), chondrogenesis (glycosaminoglycan production; SOX9 and aggrecan [ACAN] expression), myogenesis (α-smooth muscle actin expression), and neurogenesis (β-III tubulin expression) upon differentiation. CONCLUSIONS: Our findings suggest that orbital fibroblasts contain a population of cells that fulfil the criteria defining MSC. This subpopulation may be increased in GO, possibly underlying the complex differentiation phenotype of the disease.
PURPOSE:Graves' orbitopathy (GO) is a sight-threatening autoimmune disorder causing extraocular muscle fibrosis, upper lid retraction and eye bulging due to orbital fat expansion. These clinical features are mediated by aspects of orbital fibroblasts differentiation, including adipogenesis and fibrosis. Our previous work suggested that this dual phenotype might be a manifestation of mixed cell populations, partially linked to the expression of mesenchymal stem cell (MSC) marker CD90. Thus, we set out to determine whether GO orbital fibroblasts displayed MSC properties. METHODS: Control and GO orbital fibroblasts previously characterized for CD90 and CD45 expression were analyzed by flow cytometry for classical MSC positive (CD73, CD105) and negative (CD14, CD19, HLA-DR, and CD34) markers. Graves' orbitopathy fibroblasts were tested further for their ability to undergo lineage specific differentiation following standard protocols. RESULTS: Control and GO fibroblasts strongly expressed CD73 and CD105, with a higher percentage of positive cells and stronger expression levels in GO. Neither cell type expresses CD14, CD19, and HLA-DR. Protein CD34 was expressed at low levels by 45% to 70% of the cells, with its expression significantly lower in GO cells. Graves' orbitopathy fibroblasts displayed features of osteogenesis (calcium deposits, and osteocalcin [BGLAP] and osteonectin [SPARC] expression), chondrogenesis (glycosaminoglycan production; SOX9 and aggrecan [ACAN] expression), myogenesis (α-smooth muscle actin expression), and neurogenesis (β-III tubulin expression) upon differentiation. CONCLUSIONS: Our findings suggest that orbital fibroblasts contain a population of cells that fulfil the criteria defining MSC. This subpopulation may be increased in GO, possibly underlying the complex differentiation phenotype of the disease.
Authors: Eun Su Jeon; Hyun Jung Moon; Mi Jeong Lee; Hae Young Song; Young Mi Kim; Yong Chan Bae; Jin Sup Jung; Jae Ho Kim Journal: J Cell Sci Date: 2006-11-14 Impact factor: 5.285
Authors: Wolfgang Wagner; Frederik Wein; Anja Seckinger; Maria Frankhauser; Ute Wirkner; Ulf Krause; Jonathon Blake; Christian Schwager; Volker Eckstein; Wilhelm Ansorge; Anthony D Ho Journal: Exp Hematol Date: 2005-11 Impact factor: 3.084
Authors: Nathalie Billon; Palma Iannarelli; Miguel Caetano Monteiro; Corinne Glavieux-Pardanaud; William D Richardson; Nicoletta Kessaris; Christian Dani; Elisabeth Dupin Journal: Development Date: 2007-05-16 Impact factor: 6.868
Authors: Catherine J Choi; Wensi Tao; Ravi Doddapaneni; Zenith Acosta-Torres; Nathan W Blessing; Bradford W Lee; Daniel Pelaez; Sara T Wester Journal: Invest Ophthalmol Vis Sci Date: 2018-12-03 Impact factor: 4.799
Authors: Lei Zhang; Anna Evans; Chris von Ruhland; Mohd Shazli Draman; Sarah Edkins; Amy E Vincent; Rolando Berlinguer-Palmini; D Aled Rees; Anjana S Haridas; Dan Morris; Andrew R Tee; Marian Ludgate; Doug M Turnbull; Fredrik Karpe; Colin M Dayan Journal: Int J Mol Sci Date: 2020-11-30 Impact factor: 5.923
Authors: Peter N Taylor; Lei Zhang; George J Kahaly; Marian Ludgate; Richard W J Lee; Ilaria Muller; Daniel G Ezra; Colin M Dayan Journal: Nat Rev Endocrinol Date: 2019-12-30 Impact factor: 43.330
Authors: Lei Zhang; Pavandeep Rai; Satomi Miwa; Mohd Shazli Draman; D Aled Rees; Anjana S Haridas; Daniel S Morris; Andrew R Tee; Marian Ludgate; Doug M Turnbull; Colin M Dayan Journal: Endocrinology Date: 2021-12-01 Impact factor: 4.736